August 3, 2017 (Rye Brook, NY) - The Leukemia & Lymphoma Society (LLS) applauds the U.S. Food and Drug Administration (FDA) approval today of CPX-351 (VyxeosTM), an innovative combination of two chemotherapy drugs being used to treat two high-risk subgroups of acute myeloid leukemia (AML) patients. After more than four decades of little progress in treating AML, this approval marks the third drug appr...
Rye Brook, N.Y. (August 1, 2017) – Today marks another significant advance in the offensive against acute myeloid leukemia (AML), one of the most deadly blood cancers that takes more than 10,000 lives in the U.S. each year. The Leukemia & Lymphoma Society (LLS) applauds The U.S. Food & Drug Administration’s approval today of a new targeted therapy, enasidenib (IDHIFA®), for patients with AML, who ha...
Rye Brook, N.Y. (July 26, 2017) – The U.S. Senate has initiated debate on the House-passed healthcare bill, and Senate leaders are indicating they intend to advance legislation they have termed ‘skinny repeal.’ This Senate proposal would increase premiums and cost-sharing for patients who purchase their own insurance plans, while leading some insurers to stop selling non-group coverage altogether, according to ...
Rye Brook, NY (July 19, 2017) – The Leukemia & Lymphoma Society (LLS) today announced the expansion of its groundbreaking precision medicine Beat AML® Master Trial, to test new, investigational treatments for acute myeloid leukemia (AML), the central initiative of LLS’s comprehensive assault on this deadly blood cancer affecting 20,000 Americans annually. Launched in October 2016, the master trial has exc...
View multimedia release here. Rye Brook, NY (July 13, 2017) – As the leader in peer-to-peer fundraising for almost 70 years, The Leukemia & Lymphoma Society (LLS) continues to find ways to reinvent the way health charities raise vital funds for research and patient support. After pioneering non-profit sports training with Team In Training, LLS turned the traditional walk into a community experienc...
Patients Would Face New Financial Barriers to Life-Saving Treatment Rye Brook, N.Y. (June 23, 2017) – The Senate’s Better Care Reconciliation Act would exacerbate the financial and bureaucratic barriers that stand between cancer patients and life-saving treatments, based on an analysis by The Leukemia & Lymphoma Society (LLS). Below is a statement from Louis J. DeGennaro, Ph.D.,...
- LLS Community grows to nearly 5,000 users in one year -
- New collaboration with Medivizor will provide patients and caregivers with personalized, accurate and easy-to-understand medical information -
Rye Brook, N.Y. (June 15, 2017) – LLS Community, a free online network providing support and education to blood cancer patients and their caregivers, launched by The Leukemia & Lymphoma Society (LLS) i...
National Movement to Support Cancer Patients and Survivors Kicks off on June 13 View full multimedia release here. (Rye Brook, NY, June 8, 2017) – Renowned author and pop culture observer Scott Adams once said “there is no such thing as a small act of kindness. Every act creates a ripple with no logical end.” The Leukemia & Lymphoma Society (LLS) is out to prove the benefit of everyday kindness, ...
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday:
